Next Article in Journal
What Is the Role of Interleukins in Breast Cancer Bone Metastases? A Systematic Review of Preclinical and Clinical Evidence
Previous Article in Journal
Pursuing a Curative Approach in Multiple Myeloma: A Review of New Therapeutic Strategies
Open AccessArticle

Aberrant Protein Phosphorylation in Cancer by Using Raman Biomarkers

1
Laboratory of Laser Molecular Spectroscopy, Institute of Applied Radiation Chemistry, Faculty of Chemistry, Lodz University of Technology, Wroblewskiego 15, 93-590 Lodz, Poland
2
Faculty of Medicine, Medical University of Lodz, Chair of Department of Nucleic Acids Biochemistry, Pomorska 251, 92-213 Lodz, Poland
*
Author to whom correspondence should be addressed.
Cancers 2019, 11(12), 2017; https://doi.org/10.3390/cancers11122017
Received: 23 October 2019 / Revised: 3 December 2019 / Accepted: 11 December 2019 / Published: 13 December 2019
(1) Background: Novel methods are required for analysing post-translational modifications of protein phosphorylation by visualizing biochemical landscapes of proteins in human normal and cancerous tissues and cells. (2) Methods: A label-free Raman method is presented for detecting spectral changes that arise in proteins due to phosphorylation in the tissue of human breasts, small intestines, and brain tumours, as well as in the normal human astrocytes and primary glioblastoma U-87 MG cell lines. Raman spectroscopy and Raman imaging are effective tools for monitoring and analysing the vibrations of functional groups involved in aberrant phosphorylation in cancer without any phosphorecognition of tag molecules. (3) Results: Our results based on 35 fresh human cancer and normal tissues prove that the aberrant tyrosine phosphorylation monitored by the unique spectral signatures of Raman vibrations is a universal characteristic in the metabolic regulation in different types of cancers. Overexpressed tyrosine phosphorylation in the human breast, small intestine and brain tissues and in the human primary glioblastoma U-87 MG cell line was monitored by using Raman biomarkers. (4) We showed that the bands at 1586 cm−1 and 829 cm−1, corresponding to phosphorylated tyrosine, play a pivotal role as a Raman biomarker of the phosphorylation status in aggressive cancers. We found that the best Raman biomarker of phosphorylation is the 1586/829 ratio showing the statistical significance at p Values of ≤ 0.05. (5) Conclusions: Raman spectroscopy and imaging have the potential to be used as screening functional assays to detect phosphorylated target proteins and will help researchers to understand the role of phosphorylation in cellular processes and cancer progression. The abnormal and excessive high level of tyrosine phosphorylation in cancer samples compared with normal samples was found in the cancerous human tissue of breasts, small intestines and brain tumours, as well as in the mitochondria and lipid droplets of the glioblastoma U-87 MG cell line. Detailed insights are presented into the intracellular oncogenic metabolic pathways mediated by phosphorylated tyrosine. View Full-Text
Keywords: tyrosine phosphorylation; Raman spectroscopy; Raman imaging; cancer; biomarker tyrosine phosphorylation; Raman spectroscopy; Raman imaging; cancer; biomarker
Show Figures

Graphical abstract

MDPI and ACS Style

Abramczyk, H.; Imiela, A.; Brożek-Płuska, B.; Kopeć, M.; Surmacki, J.; Śliwińska, A. Aberrant Protein Phosphorylation in Cancer by Using Raman Biomarkers. Cancers 2019, 11, 2017.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop